



# Breast Cancer Factsheet: Insights & Key Developments

Key Insights on Breast Cancer Care and Infrastructure

#### Core Pillars:

- 1. Infrastructure
- 2. Treatment Access, Research Funding and Awareness Campaigns
- 3. Survival Rates, Early Detection and Palliative Care
- 4. Utilization of Biomarkers
- 5. Clinical Guidelines
- 6. Reimbursement
- 7. Breast Cancer Screening

Breast cancer remains one of the most prevalent cancers worldwide, affecting millions of individuals each year. Despite advancements in diagnostics, treatment, and awareness, disparities in access to care, molecular testing, and specialized centers persist.

This factsheet provides a comprehensive overview of key pillars shaping breast cancer care, including specialized infrastructure, treatment accessibility, research funding, early detection, and palliative care. By analyzing these critical aspects, we aim to highlight gaps, policy challenges, and areas for improvement in breast cancer management.

- Breast cancer incidence: 29.5% of all female cancers
- Incidence rate: 57.8 per 100,000 women per year
- Total cases (2018-2022): 23,226 reported cases
- Lifetime risk in Chile: 1 in 14 women
- Daily diagnoses: ~13 women per day
- Breast cancer deaths (2018-2022): ~18.5% of total cases
- 5-year survival rate: ~85% (varies by stage)
- Stage I diagnosis increase: 28% (2008-2012) → 52% (2018-2022)
- Young women cases: 17.3% under 45 years old
- Most affected age group: 50-59 years
- Mammogram detection: 45% via screening programs
- Screening participation (ages 50-69): Only 38%



# Chile Land Infrastructure


#### Strengths

- HER2, ER, and PR testing available in most urban cancer centers.
- National GES program supports access to basic diagnostics and treatments.

0

### Opportunity

- Expand public sector genomic capacity and precision oncology initiatives.
- Integrate regional labs with telemedicine and national cancer databases.



 BRCA and NGS testing limited in public sector and rural regions.

Weakness

 Public labs face underfunding and equipment shortages.

- Delays in molecular test adoption could widen care disparities.
- Budget constraints may hinder implementation of emerging technologies.

widespread availability in public and prival sectors, integration with clinical practice	5. Advanced nationwide infrastructure,
---	--

- 4. Strong infrastructure in major hospitals and cancer centers, some regional disparities.
- 3. Moderate infrastructure, primarily in private settings or research institutions.
- 2. Limited infrastructure, available only in select centers or for high-cost private testing.
- 1. Minimal or no infrastructure, testing mostly unavailable or sent abroad.

Country	Specialized Centers	Genetic & Molecular Testing Infrastructure
South Africa	0	<u> </u>
Kenya		
Nigeria		
Egypt	<u> </u>	
Morocco		
Algeria		
Ethiopia		
India		
Japan		
South Korea		
China		
Thailand	<u> </u>	
Singapore		
United Kingdom		
Germany		
France		
Netherlands		
Sweden		
Italy		
Spain		
Poland	<u> </u>	<u> </u>
Mexico		
Brazil	<u> </u>	<u> </u>
Argentina	<u> </u>	<u> </u>
Chile	<u> </u>	<u> </u>
Colombia		
United States		
Canada		
Australia		
New Zealand		
Greece	<u> </u>	<u> </u>
Rwanda		
Uganda		
Serbia	<u> </u>	0
Saudi Arabia	<u> </u>	0
UAE	0	
Syria		
Indonesia		
Vietnam	0	
Philippines		
Russia		



## Chile \*

Treatment Access, Research Funding and Awareness Campaigns

#### Strengths

- GES covers surgery, chemotherapy, radiation, and hormonal therapy.
- Government and ANID are investing in oncology research.

## S 0

#### Weakness

- CDK4/6 and PARF inhibitors limited public system; require special approval.
- Screening participation remains low at 38%, especially i rural areas.

#### Opportunity

- Increase coverage of advanced therapies through GES expansion.
- Launch communitytargeted awareness campaigns to boost screening.

Threats

- Out-of-pocket treatment costs drive inequities in care access.
- Public hospitals overwhelmed by demand for nove therapies.

of structured awareness campaigns. Cancer care is largely inaccessible, with many patients relying on out-of-pocket expenses or external aid.

		C
		So
ar <del>'</del>		1
*		
2.7		So
1		
		-
		S
Į.		Unit
		Nic
RP	15	Ne
d in		
	5. Strong healthcare infrastructure with	
	comprehensive treatment access, high research funding, and nationwide awareness campaigns.	
	Patients have access to advanced therapies, clinical	
	trials, and widespread early detection programs.	Д
in	4. Well-developed system with good treatment availability, strong research funding, and effective but	
	regionally focused awareness campaigns. Some	11:00
	disparities may exist in rural areas or between public and private sectors.	Uni
	3. Moderate development, with specialized treatments available in major hospitals, research	Ne
	funding concentrated on specific cancers, and occasional but limited awareness efforts. Healthcare	
S	access may be restricted by cost or geography.	
in	2. Limited system where cancer treatment is available	
	only in select urban centers, research funding is minimal or sporadic, and awareness campaigns are rare or	
	underfunded. Patients often face long wait times or financial barriers.	Sa
/	1. Poor infrastructure with severe barriers to	
rel	treatment, little to no research funding, and lack	1.
	of structured awareness campaigns. Cancer care	li li

Country	Treatment Access	Research Funding	Awareness Campaigns
South Africa	0	<u> </u>	<u> </u>
Kenya			
Nigeria			
Egypt	0	<u> </u>	<u> </u>
Morocco			<u> </u>
Algeria			
Ethiopia			
India	<u> </u>	0	<u> </u>
Japan			
South Korea			
China			
Thailand			
Singapore			
United Kingdom			
Germany			
France			
Netherlands			
Sweden			
Italy			
Spain	0		
Poland	<u> </u>		$\bigcirc$
Mexico			$\bigcirc$
Brazil	<u> </u>	<u> </u>	
Argentina	0	<u> </u>	$\bigcirc$
Chile		<u> </u>	$\bigcirc$
Colombia			
United States			
Canada			
Australia	0		
New Zealand	0	<u> </u>	0
Greece	0	<u> </u>	<u> </u>
Rwanda			
Uganda			
Serbia	<u> </u>	<u> </u>	<u> </u>
Saudi Arabia	0	0	0
UAE	0	0	0
Syria	0		
Indonesia	0	<u> </u>	0
Vietnam	0	<u> </u>	<u> </u>
Philippines	0		<u> </u>
Russia			$\bigcirc$



## Chile \*

Survival Rates, Early **Detection** and Palliative Care

#### Strengths

- 5-year survival rate improving (~85%); Stage I diagnoses rising.
- Palliative care available in major centers.

Opportunity

### Weaknes

- Access to e diagnosis and palliative care uneven outside urban areas.
- Long diagnostic delays in public sector reduce treatment effectiveness.

#### **Threats**

 Increase mobile Inadequate early detection may stall screening and pain management outreach further survival rate in rural zones. gains.

0

 Strengthen primary care Socioeconomic status integration with early remains a major detection efforts. determinant of care quality.

5. High survival rates, strong early detection iative care imely diagnosis,

> 4. Good survival rates, effective early detection efforts, and accessible but regionally limited


> > 3. Moderate survival rates, early detection available but not widespread, and palliative care services mainly in urban centers. Some patients experience delays in diagnosis or limited end-of-life

2. Low survival rates, early detection efforts are inconsistent or underfunded, and palliative care is minimal or only available in select hospitals. Cancer patients face significant access barriers.


1. Very low survival rates, poor early detection infrastructure, and almost no palliative care services. Many patients are diagnosed late and lack proper support for pain management and end-of-life care.

2.5			
SS			
early nd	1	5	<b>1</b>


	programs, and well-established palliative care services. Patients have access to timely diagnosis, advanced treatments, and comprehensive end-of-life care.







care.



Country	Survival Rates	Early Detection	Palliative Care
South Africa	0	<u> </u>	<u> </u>
Kenya			
Nigeria			
Egypt	0	<u> </u>	<u> </u>
Morocco	0	<u> </u>	<u> </u>
Algeria			
Ethiopia			
India	0	<u> </u>	<u> </u>
Japan	0	0	0
South Korea	0		
China	0	<u> </u>	<u> </u>
Thailand	0	<u> </u>	<u> </u>
Singapore	0		0
United Kingdom			
Germany			
France			
Netherlands			
Sweden			
Italy			
Spain			
Poland	0	0	0
Mexico		0	
Brazil	0	0	0
Argentina	0	0	0
Chile		0	0
Colombia		0	
United States			
Canada			
Australia			
New Zealand	0		0
Greece	0	0	
Rwanda			
Uganda			
Serbia	0	0	0
Saudi Arabia			
UAE			
Syria			
Indonesia			
Vietnam	0	0	
Philippines	0	0	0
Russia		<u> </u>	<u> </u>
	<del>-</del>		_



# Chile La Utilization of Biomarkers

#### Strengths

- HER2/ER/PR testing standard in most specialized urban centers.
- BRCA testing available in private sector and partially covered for some.

0

#### Opportunity


- Improve insurance coverage and subsidies for genetic testing.
- Scale NGS platforms through academicclinical collaboration.

## Weakness

- Only 40-50% of highrisk patients access BRCA testing due to cost.
- NGS and advanced diagnostics rare in public system.

- Delayed biomarker use may prevent optimal treatment plans.
- Financial barriers risk entrenching two-tier access to precision care.

- 5. 80% Biomarker testing is widely available and routinely performed as part of standard clinical practice. Strong integration into treatment decisions, with national coverage and reimbursement ensuring accessibility.
  - 4. 61-80%. Biomarker testing is commonly used, but access may be limited in certain regions or patient groups. Some disparities exist in coverage or affordability, but it is still a crucial part of cancer diagnostics
  - 41-60% Moderate utilization, often restricted to major hospitals or private healthcare settings.
     Some patients may not receive biomarker testing due to cost or limited availability in public healthcare systems.
  - 2. 20-40% Biomarker testing is available but underutilized, with significant barriers such as high costs, lack of awareness, or limited infrastructure. Many patients may not receive recommended biomarker assessments.
  - 1. <20% Biomarker testing is rarely performed, often due to lack of infrastructure, awareness, or financial barriers. Patients typically do not receive targeted therapies based on biomarker status.









#### Strengths

- National protocols align with ESMO/NCCN and are applied in major centers.
- Santiago and Valparaíso support multidisciplinary, evidence-based care.

0

#### Opportunity

- Digitally distribute guideline updates and provide CME support.
- Standardize care pathways through national audits and quality programs.

#### Weakness

- Limited implementation capacity in rural areas with few specialists.
- Budget limitations slow real-time uptake of new guidelines.

- Fragmentation in implementation could lower overall care quality.
- Rural centers risk falling behind as new global recommendations emerge.



	Very High	High	Medium	Low	Very Low
Clinical Guideline Implementation	*	0	*	×	*
Feasibility of Integration	*	0	*	*	*
Adoption of International Guidelines	*	0	*	*	*
Engagement with Updates	*	*	0	*	*
ESMO Guidelines Implementation	*	0	*	*	*



# Chile \*\* Reimbursement



#### Strengths

- GES provides nocost access to standard treatments in public hospitals.
- HER2-positive therapies like trastuzumab included in public coverage.

0

#### Opportunity

- Expand public reimbursement to cover precision therapies and diagnostics.
- Develop co-financing or support programs for high-cost medications.

#### Weakness

- Targeted drugs (e.g., CDK4/6, PARP inhibitors) require special approval.
- Out-of-pocket treatment costs often exceed \$2,000-3,500/month.

- High private-sector costs create access inequities.
- Legal appeals and delays limit timely treatment in public system.



- A structured reimbursement system exists, ensuring biomarker testing is covered through national healthcare systems, insurance, or public-private partnerships. Patients face no direct financial burden.
- A reimbursement framework is in place, but patients may still have out-of-pocket expenses such as copays, limited coverage, or financial caps on testing.
- No formal reimbursement system exists, meaning patients must fully cover the cost of biomarker testing out-of-pocket.

Country	Reimbursement	No-cost Access
South Africa	0	×
Kenya	×	<b>X</b>
Nigeria	×	*
Egypt	0	0
Morocco	0	×
Algeria	0	×
Ethiopia	×	×
India	0	×
Japan	0	0
South Korea	0	0
China	0	0
Thailand	0	0
Singapore	0	0
United Kingdom	0	0
Germany	0	0
France	0	0
Netherlands	0	0
Sweden	0	0
Italy	0	0
Spain	0	0
Poland	0	0
Mexico	0	×
Brazil	0	×
Argentina	0	×
Chile	0	0
Colombia	0	×
United States	0	0
Canada	0	0
Australia	0	0
New Zealand	0	0
Greece	0	0
Rwanda	×	×
Uganda	×	×
Serbia	0	0
Saudi Arabia	0	0
UAE	0	0
Syria	0	0
Indonesia	0	0
Vietnam	×	×
Philippines	×	×
Russia	0	0





#### Strengths

- National program provides mammograms every 3 years (ages 50-69).
- Awareness efforts and mobile units aim to expand reach.

## W 0

#### Weakness

- Screening coverage at just 38%; long public hospital wait times.
- Imaging capacity and specialist shortages hinder early detection.

#### Opportunity

- Expand screening to high-risk groups with MRI and mobile units.
- Improve equity via education and outreach in Indigenous and rural areas.

- Without increased investment, coverage gaps will persist.
- Late diagnoses could offset national progress in survival.

Country	Breast Cancer Screening
United States	Biennial mammograms (50-74 years)
United Kingdom	Triennial mammograms (50-71 years)
Canada	Mammograms every 2-3 years (50-74 years)
Australia	Biennial mammograms (50-74 years)
Germany	Mammograms every 2 years (50-69 years)
France	Biennial mammograms (50-74 years)
Netherlands	Mammograms every 2 years (50-75 years)
Sweden	Mammograms every 18-24 months (40- 74 years)
Italy	Mammograms every 2 years (50-69 years)
Spain	Mammograms every 2 years (50-69 years)
Poland	Mammograms every 2 years (50-69 years)
Japan	Mammograms every 2 years (40+ years)
South Korea	Biennial mammograms (40+ years)
China	Regional mammogram programs (40-69 years)
India	Opportunistic screening
Singapore	Biennial mammograms (50-69 years)
Saudi Arabia	Opportunistic screening; regional programs for women aged 40+
UAE	Opportunistic screening; encouraged every 2 years for 40-69 years
Syria	No national program; limited local initiatives due to conflict

Country	Breast Cancer Screening
Thailand	Biennial mammograms (50-69 years)
South Africa	Opportunistic screening
Kenya	No national program
Nigeria	No national program
Egypt	National awareness campaigns
Morocco	National program for 45-69 years
Algeria	Planned national program (50-69 years)
Ethiopia	No national program
Mexico	Biennial mammograms (40-69 years)
Brazil	Biennial mammograms (50-69 years)
Argentina	Biennial mammograms (50-69 years)
Chile	Mammograms every 3 years (50-69 years)
Colombia	Biennial mammograms (50-69 years)
New Zealand	Biennial mammograms (45-69 years)
Greece	Biennial mammograms (50-69 years)
Rwanda	No national program
Uganda	No national program
Serbia	Biennial mammograms (50-69 years)
Indonesia	Opportunistic screening; no national mammography program
Vietnam	Regional mammography programs; pilot programs in urban areas (age 45-69)
Philippines	Opportunistic screening; mammography recommended every 2 years for women 50+
Russia	National program for biennial mammograms (50-69 years)